Trials / Completed
CompletedNCT01749956
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiation | |
| DRUG | Aflibercept | |
| PROCEDURE | Surgery | Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines |
| DRUG | FOLFOX6 |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2012-12-17
- Last updated
- 2017-02-07
- Results posted
- 2017-02-07
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01749956. Inclusion in this directory is not an endorsement.